Victoria Blinder

4.7k total citations · 2 hit papers
80 papers, 2.7k citations indexed

About

Victoria Blinder is a scholar working on Oncology, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Victoria Blinder has authored 80 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 38 papers in Economics and Econometrics and 12 papers in Cancer Research. Recurrent topics in Victoria Blinder's work include Economic and Financial Impacts of Cancer (37 papers), Health Systems, Economic Evaluations, Quality of Life (20 papers) and Cancer survivorship and care (19 papers). Victoria Blinder is often cited by papers focused on Economic and Financial Impacts of Cancer (37 papers), Health Systems, Economic Evaluations, Quality of Life (20 papers) and Cancer survivorship and care (19 papers). Victoria Blinder collaborates with scholars based in United States, Canada and Australia. Victoria Blinder's co-authors include Pricivel M. Carrera, Hagop M. Kantarjian, Francesca Gany, Sujata Patil, David Cella, Jennifer J. Griggs, Christopher K. Daugherty, Kristen Wroblewski, Fay J. Hlubocky and Bonnie J. Yap and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Victoria Blinder

75 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment

2018 614 citations Victoria Blinder et al. profile →
Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

2016 585 citations Victoria Blinder et al. Cancer profile →

Peers

Countries citing papers authored by Victoria Blinder

Since Specialization

Citations

This map shows the geographic impact of Victoria Blinder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Blinder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Blinder more than expected).

Fields of papers citing papers by Victoria Blinder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Blinder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Blinder. The network helps show where Victoria Blinder may publish in the future.

Co-authorship network of co-authors of Victoria Blinder

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Blinder. A scholar is included among the top collaborators of Victoria Blinder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Blinder. Victoria Blinder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Provider billing margin and cancer treatment selection: population based cohort study 2025 ·BMJ ·Aaron Philip Mitchell, Stacie B. Dusetzina, (unknown), (unknown), (unknown), Hannah E. Fuchs, Grace Guzman, (unknown), Sara Tabatabai, (unknown), (unknown), Victoria Blinder, Andrew S. Epstein, (unknown), Aaron N. Winn, Mithat Gönen	0
2	Screened but Still Struggling: Challenges in Delivering Financial Assistance After Positive Financial Toxicity Screens 2025 ·JCO Oncology Practice ·(unknown), Amy L. Tin, (unknown), (unknown), Francesca Gany, (unknown), (unknown), (unknown), (unknown), (unknown), Victoria Blinder, Emeline Aviki, Andrew J. Vickers, Fumiko Chino, Bridgette Thom	0
3	Quality of Treatment Selection for Medicare Beneficiaries With Cancer 2024 ·Journal of Clinical Oncology ·Aaron Philip Mitchell, (unknown), (unknown), Hannah E. Fuchs, Prabal K. De, Sara Tabatabai, (unknown), (unknown), Niti U. Trivedi, Sham Mailankody, Victoria Blinder, Angela Green, Andrew S. Epstein, (unknown), Lindsey E. Roeker, Peter B. Bach, Mithat Gönen	3
4	Trends in exercise initiation and participation among employed breast cancer survivors undergoing curative treatment 2024 ·Breast Cancer Research and Treatment ·(unknown), Sujata Patil, (unknown), Francesca Gany, Victoria Blinder	0
5	An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial 2022 ·Trials ·Victoria Blinder, Sujata Patil, Jackie Finik, Della Makower, (unknown), Wendy G. Lichtenthal, Patricia A. Parker, (unknown), (unknown), (unknown), Francesca Gany	12
6	Risk factors for financial toxicity in patients with gynecologic cancer 2021 ·American Journal of Obstetrics and Gynecology ·Emeline Aviki, Beryl Manning‐Geist, (unknown), Tiffanny Newman, Victoria Blinder, Fumiko Chino, (unknown), (unknown), Sushmita Gordhandas, Carol L. Brown, Vance Broach, S. Dennis, Elizabeth L. Jewell, Mario M. Leitão, Kara Long Roche, Jennifer J. Mueller, Yukio Sonoda, Oliver Zivanovic, Ginger J. Gardner, Nadeem R. Abu‐Rustum	37
7	Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer 2021 ·Future Oncology ·Ciara C. O’Sullivan, Karla V. Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss, Melissa P. Mitchell, Victoria Blinder, Nadine Tung, William Irvin, Myoung-Hee Lee, Matthew P. Goetz, W. Fraser Symmans, Virginia F. Borges, Ian E. Krop, Lisa A. Carey, Ann H. Partridge	19
8	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic 2021 ·Breast Cancer Research and Treatment ·Ko Un Park, Megan E. Gregory, (unknown), Maryam B. Lustberg, Shoshana M. Rosenberg, Victoria Blinder, Priyanka Sharma, Lajos Pusztai, Chengli Shen, Ann H. Partridge, Alastair M. Thompson	27
9	A Technology-Assisted, Brief Mind-Body Intervention to Improve the Waiting Room Experience for Chemotherapy Patients: Randomized Quality Improvement Study 2019 ·JMIR Cancer ·Ting Bao, Gary Deng, (unknown), Wanqing Iris Zhi, (unknown), Victoria Blinder, Connie Chen, Qing S. Li, Jamie Green, (unknown), Jun J. Mao	6
10	Living with chronic pain: perceptions of breast cancer survivors 2018 ·Breast Cancer Research and Treatment ·Ting Bao, Andrew D. Seidman, Qing Li, Christina Seluzicki, Victoria Blinder, Salimah H. Meghani, John T. Farrar, Jun J. Mao	23
11	Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis 2018 ·Breast Cancer Research and Treatment ·Angela K. Green, Emeline Aviki, Konstantina Matsoukas, Sujata Patil, Deborah Korenstein, Victoria Blinder	51
12	American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations 2017 ·Obstetrical & Gynecological Survey ·Jennifer J. Griggs, Shail Maingi, Victoria Blinder, Neelima Denduluri, Alok A. Khorana, Larry Norton, Michael Francisco, Dana S. Wollins, Julia H. Rowland	12
13	Provider Differences in Use of Implanted Ports in Older Adults With Cancer 2015 ·Medical Care ·Allison Lipitz‐Snyderman, Elena B. Elkin, Coral L. Atoria, Camelia S. Sima, Andrew S. Epstein, Victoria Blinder, Kent A. Sepkowitz, Peter B. Bach	8
14	Health Disparities and the Cancer Survivor 2013 ·Seminars in Oncology ·Victoria Blinder, Jennifer J. Griggs	20
15	Cost‐effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer 2013 ·Cancer ·(unknown), Elena B. Elkin, Victoria Blinder, Nancy L. Keating, Niteesh K. Choudhry	12
16	Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program 2012 ·Cancer ·Ann H. Partridge, Virginia W. Norris, Victoria Blinder, (unknown), Michael T. Halpern, Jennifer L. Malin, Michael N. Neuss, Antonio C. Wolff, (unknown)	12
17	Patient perspectives on breast cancer treatment plan and summary documents in community oncology care 2012 ·Cancer ·Victoria Blinder, Virginia W. Norris, N. W. Peacock, Jennifer J. Griggs, David P. Harrington, Anne Moore, Richard L. Theriault, Ann H. Partridge	42
18	Return to work in low‐income Latina and non‐Latina white breast cancer survivors: A 3‐year longitudinal study 2011 ·Cancer ·Victoria Blinder, Sujata Patil, Amardeep Thind, Allison Diamant, Clifford A. Hudis, Ethan Basch, Rose C. Maly	78
19	Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer 2009 ·Cancer ·Heather T. Gold, Michael J. Hall, Victoria Blinder, Bruce R. Schackman	65
20	Review: Improving Outcomes for Patients with Burkitt Lymphoma and HIV 2008 ·AIDS Patient Care and STDs ·Victoria Blinder, Amy Chadburn, Richard R. Furman, Susan Mathew, John P. Leonard	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact